Serum ferritin as a marker of clinical and histopathological response to treatment in lupus nephritis

被引：0
|
作者：
Parodis, I. [1 ]
Ding, H. [2 ]
Zickert, A. [1 ]
Arnaud, L. [1 ]
Mohan, C. [2 ]
Gunnarsson, I. [1 ]
机构：
[1] Karolinska Inst, Karolinska Univ Hosp, Stockholm, Sweden
[2] Univ Houston, Houston, TX 77004 USA
来源：
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | 2016年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP51
引用
收藏
页码：40 / 41
页数：2
相关论文
共 50 条
  • [1] SERUM FERRITIN AS A MARKER OF CLINICAL AND HISTOPATHOLOGICAL RESPONSE TO TREATMENT IN LUPUS NEPHRITIS
    Parodis, I.
    Ding, H.
    Zickert, A.
    Arnaud, L.
    Mohan, C.
    Gunnarsson, I.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S75 - S75
  • [2] SERUM FERRITIN AS A BIOMARKER OF CLINICAL AND HISTOPATHOLOGICAL RESPONSE TO TREATMENT IN LUPUS NEPHRITIS
    Parodis, I.
    Ding, H.
    Zickert, A.
    Arnaud, L.
    Mohan, C.
    Gunnarsson, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1063 - 1063
  • [3] Serum Ferritin and Insulin-like Growth Factor-Binding Protein 2 As Biomarkers of Clinical and Histopathological Treatment Response in Lupus Nephritis
    Parodis, Ioannis
    Ding, Huihua
    Zickert, Agneta
    Mohan, Chandra
    Gunnarsson, Iva
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [4] Clinical and Histopathological Profile of Lupus Nephritis and Response to Treatment with Cyclophosphamide: A Single Center Study
    Sharma, Manjuri
    Das, Himanab Jyoti
    Doley, Prodip Kumar
    Mahanta, Pranab Jyoti
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2019, 30 (02) : 501 - 507
  • [5] Histopathological and clinical response in proliferative lupus nephritis patients treated with rituximab
    Gunnarsson, Iva
    Jonsdottir, Thorunn
    Sundelin, Birgitta
    Jacobson, Stefan
    van Vollenhoven, Ronald
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2006, 35 : 11 - 12
  • [6] Urinary epidermal growth factor as a marker for lupus nephritis: clinical, laboratory, and histopathological study
    Hefny, Hesham M.
    Abualfadl, Esam M.
    Youssef, Emad A. M.
    Ismail, Mohamed Ali
    Soliman, Tamer M.
    Ahmed, Ahmed Roshdi Hamed
    Abozaid, Hanan S. M.
    EGYPTIAN RHEUMATOLOGY AND REHABILITATION, 2024, 51 (01)
  • [7] Urinary epidermal growth factor as a marker for lupus nephritis: clinical, laboratory, and histopathological study
    Hefny, Hesham M.
    Abualfadl, Esam M.
    Youssef, Emad A. M.
    Ismail, Mohamed Ali
    Soliman, Tamer M.
    Ahmed, Ahmed Roshdi Hamed
    Abozaid, Hanan S. M.
    EGYPTIAN RHEUMATOLOGY AND REHABILITATION, 2021, 48 (01)
  • [8] The clinical manifestations and response to treatment in South Africans with lupus nephritis
    Mody, P. G.
    Mody, G. M.
    Assounga, A.
    LUPUS, 2018, 27 (07) : 1207 - 1217
  • [9] Treatment of childhood lupus nephritis (LN) with mycophenolate mofetil (MMF): Clinical and histopathological study
    Caropreso, M.
    Nuzzi, F.
    Malgieri, G.
    Marzano, L.
    D'Armiento, M.
    Balletta, M.
    Indaco, R.
    Pecoraro, C.
    PEDIATRIC NEPHROLOGY, 2007, 22 (09) : 1469 - 1469
  • [10] SERUM INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 2 (IGFBP2) AS A BIOMARKER OF CLINICAL AND HISTOPATHOLOGICAL TREATMENT RESPONSE IN LUPUS NEPHRITIS
    Parodis, I.
    Ding, H.
    Zickert, A.
    Arnaud, L.
    Mohan, C.
    Gunnarsson, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 547 - 547
12345